FindTrial
Sign In

Safety and efficacy study of Risk-Reducing salpingo-oopholectomy in BRCA1/2 mutant carriers

Safety and efficacy study of Risk-Reducing salpingo-oopholectomy in BRCA1/2 mutant carriers - Cohort Study of Risk Reducing Salpingo-oophlectomy in HBOC

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015021
Enrollment
20
Registered
2014-09-30
Start date
2016-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Breast and Ovarian Cancer syndrome: HBOC

Interventions

risk reducing salpingo-oophorectomy: RRSO

Sponsors

Okayama university hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. BRCA1/2 mutant carriers 2. Tolerability to RRSO 3. informed consent

Exclusion criteria

Exclusion criteria: 1. Women with tubular or ovarian disease 2. physicians decision

Design outcomes

Primary

MeasureTime frame
Adverse event related to RRSO—

Countries

Japan

Contacts

Public ContactNaruto Taira

Okayama University Hospital Department of Breast and Endocrine Surgery

ntaira@md.okayama-u.ac.jp086-235-7265

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026